The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).

4614 Background: Approximately 75% of patients (pts) with advanced BC or PC will develop bone metastases (BM), which influence bone metabolism and increase the incidence of skeletal related events ...